Cisapride class-action suit approved

Comeau, Pauline
February 2007
CMAJ: Canadian Medical Association Journal;2/27/2007, Vol. 176 Issue 5, p615
Academic Journal
The article discusses the class-action lawsuit filed against Janssen-Ortho Inc. and the Attorney General of Canada. The class-action lawsuit was certified by an Ontario Superior Court Justice on behalf of the Canadians who have medicated themselves with the antireflux drug Cisapride (Prepulsid). The lawsuit was filed against the respondents following the death of a patient with heart arrhythmia after taking Cisapride.


Related Articles

  • Efficacy and Tolerability of Cisapride in Children. vandenplas, Y.; Benatar, A.; Cools, F.; Arana, A.; Hegar, B.; Hauser, B. // Pediatric Drugs;2001, Vol. 3 Issue 8, p559 

    As gastro-oesophageal reflux disease (GORD) in infants and children is a motility disorder which differs in pathophysiology and clinical course from GORD in adults, prokinetics should be considered the drug of choice in certain circumstances. Indeed, cisapride may result in improvement of...

  • Clinical Q & A. Castellanos, Julie T.; Rosenberg, Jack M. // Drug Topics;7/3/2000, Vol. 144 Issue 13, p20 

    Suggests alternatives to Propulsid (cisapride). Side effects of Propulsid intake; Metabolism of the drug; Alternative treatment for patients with gastroesophageal reflux disease.

  • Facilitating antidepressant use. R.M.D. // Cortlandt Forum;9/25/96, Vol. 9 Issue 9, p124 

    Suggests the use of cisapride Propulsid in managing a patient who is complaining of constipation while having a lifesaving response to tricyclic antidepressants. Counter suggestion to use a laxative intermittently.

  • Antireflux surgery. Taylor, T.V.; Holt, S. // BMJ: British Medical Journal (International Edition);6/23/90, Vol. 300 Issue 6740, p1603 

    Focuses on issues related to surgery to treat gastroesophageal reflux. Administration of the drug cisapride; Concern over the development of hypergastrinemia; Aim of correcting hiatus defect.

  • Cisapride (Prepulsid): interactions with grapefruit and drugs. Morawiecka, Iza // CMAJ: Canadian Medical Association Journal;1/11/2000, Vol. 162 Issue 1, p105 

    Reports on cisapride monohydrate (Prepulsid), an oral gastrointestinal prokinetic agent indicated in the symptomatic management of motility disorders. Suspected adverse drug reactions (ADRs) reported to the Canadian Adverse Drug Reaction Monitoring Program; Postmarketing surveillance of the...

  • Alternative treatment for reflux takes a step-down approach. Kahrilas, Peter J. // Modern Medicine;Sep97, Vol. 65 Issue 9, p36 

    Presents a physician's suggestion of an alternative approach to the treatment of gastroesophageal reflux disease. Starting with a proton-pump inhibitor such as omeprazole or lansoprazole; Finishing with an H2 blocker or pro-motility drug such as ranitidine or cisapride; Standard escalating...

  • How accurately can QT interval be measured in newborn infants? De Groote, Katya; Suys, Bert; Deleeck, An; De Wolf, Daniël; Matthys, Dirk; Overmeire, Bart Van; De Wolf, Daniël; Van Overmeire, Bart // European Journal of Pediatrics;2003, Vol. 162 Issue 12, p875 

    Unlabelled: We determined inter- and intra-observer variability of measurements of QT and heart rate corrected QT (QTc) interval in newborn infants. In 55 newborns, a standard 12-lead electrocardiogram (ECG) with rhythm strip was analysed independently by three observers. QT and the...

  • Cisapride for treatment of esophageal reflux.  // American Family Physician;8/1/1995, Vol. 52 Issue 2, p649 

    Reports on the study made by Richter and Long evaluating the effectiveness of cisapride, a prokinetic agent used in the treatment of gastroesophageal reflux. Original article appeared in the March 1995 issue of `American Journal of Gastoenterology'; Enrollment of patients with heartburn and...

  • Cisapride in Infants. Mack, D. R.; Thompson, Jon S. // American Journal of Gastroenterology;Aug1999, Vol. 94 Issue 8, p2008 

    Discusses a study which used cisapride in the control of symptoms in infants with gastroesophageal reflux. Reason that agents such as bethanacol and metoclopramide are rarely used anymore in infants; Need to weigh a balance between therapeutic benefit and risks to the patient by the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics